Esperion Therapeutics Inc. (NASDAQ: ESPR) on Friday, soared 3.51% from the previous trading day, before settling in for the closing price of $1.71. Within the past 52 weeks, ESPR’s price has moved between $0.70 and $3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 7.64%. The company achieved an average annual earnings per share of 88.18%. With a float of $194.07 million, this company’s outstanding shares have now reached $196.22 million.
Let’s determine the extent of company efficiency that accounts for 240 employees. In terms of profitability, gross margin is 81.81%, operating margin of 1.78%, and the pretax margin is -35.46%.
Esperion Therapeutics Inc. (ESPR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc. is 1.10%, while institutional ownership is 72.42%. The most recent insider transaction that took place on Aug 19 ’24, was worth 411. In this transaction Chief Commercial Officer of this company sold 211 shares at a rate of $1.95, taking the stock ownership to the 165,267 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Officer proposed sale 211 for $1.95, making the entire transaction worth $410.
Esperion Therapeutics Inc. (ESPR) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -0.43) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 88.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc. (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.49 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.20 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Looking closely at Esperion Therapeutics Inc. (NASDAQ: ESPR), its last 5-days average volume was 3.95 million, which is a drop from its year-to-date volume of 7.07 million. As of the previous 9 days, the stock’s Stochastic %D was 11.10%. Additionally, its Average True Range was 0.14.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 3.55%, which indicates a significant decrease from 14.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.86% in the past 14 days, which was lower than the 84.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2606, while its 200-day Moving Average is $2.2082. However, in the short run, Esperion Therapeutics Inc.’s stock first resistance to watch stands at $1.8100. Second resistance stands at $1.8500. The third major resistance level sits at $1.8950. If the price goes on to break the first support level at $1.7250, it is likely to go to the next support level at $1.6800. Now, if the price goes above the second support level, the third support stands at $1.6400.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 347.31 million based on 189,460K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 73,830 K in profit during its latest quarter, and -61,930 K in sales during its previous quarter.
